Sponsor Check › Person
Related person on Form D filings · address state as listed: MA · listed Jul 27, 2009 → Jun 10, 2022
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:57 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:57 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 35 offerings report sales commissions; 0 report finder's fees; 1 reports proceeds to related persons totalling $35,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 10, 2022 D File 021-448880 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will be a percentage of the aggregate subscriptions of the Issuer's limited partners. | None listed on this filing |
| EDGAR ↗ | Dec 22, 2020 D File 021-384105 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2020 D File 021-379231 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 8, 2019 D File 021-350552 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 7, 2019 D File 021-341395 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will be a percentage of the aggregate subscriptions of the Issuer's limited partners. | None listed on this filing |
| EDGAR ↗ | Apr 6, 2018 D File 021-309534 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 13, 2017 D/A File 021-278190 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2016 D File 021-273650 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will be a percentage of the aggregate subscriptions of the Issuer's limited partners. | None listed on this filing |
| EDGAR ↗ | Sep 27, 2016 D File 021-271333 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 13, 2016 D File 021-261236 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 15, 2015 D File 021-253071 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 10, 2015 D File 021-252792 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 19, 2015 D File 021-246095 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 29, 2015 D File 021-238833 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 13, 2014 D File 021-228271 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 5, 2014 D File 021-222326 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 24, 2014 D File 021-216153 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 25, 2013 D File 021-193854 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will be a percentage of the aggregate subscriptions of the Issuer's limited partners. | None listed on this filing |
| EDGAR ↗ | Feb 28, 2013 D File 021-192576 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 14, 2012 D File 021-188408 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 25, 2012 D File 021-181718 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 14, 2012 D File 021-174916 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 15, 2011 D File 021-170146 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 6, 2011 D File 021-160851 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2011 D/A File 021-66444 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 27, 2011 D File 021-158958 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 19, 2010 D File 021-150787 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 10, 2010 D File 021-150327 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2010 D File 021-148928 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 9, 2010 D File 021-143174 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 2, 2010 D File 021-142827 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 15, 2010 D File 021-140660 | $0 | $0 | $35,000 (est.) | None listed on this filing |
| EDGAR ↗ | Apr 9, 2010 D File 021-140348 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of the aggregate subscriptions of the Issuer's limited partners. | None listed on this filing |
| EDGAR ↗ | Feb 4, 2010 D File 021-123629 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 27, 2009 D File 021-104032 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Third Rock Ventures VI, L.P. group: Third Rock | Executive Officer Manager of the GPLLC. | Jun 10, 2022 | D | $1,105,340,000 similar: $155,000–$5,250,000 | $1,105,340,000 | 65 similar: 4–27 | $500,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Faze Medicines, Inc. | Director | Dec 22, 2020 | D | $81,000,000 similar: $2,000,000–$19,999,994 | $30,375,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Jounce Therapeutics, Inc. | Director | Oct 29, 2020 | D | $34,999,995 similar: $2,000,000–$19,999,994 | $34,999,995 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Oct 8, 2019 | D | $64,999,985 similar: $2,000,000–$19,999,994 | $64,999,985 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Third Rock Ventures V, L.P. group: Third Rock | Executive Officer Manager of the GPLLC. | Jun 7, 2019 | D | $750,000,000 similar: $155,000–$5,250,000 | $750,000,000 | 67 similar: 4–27 | $200,000 similar: $1,000–$100,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Apr 6, 2018 | D | $100,000,000 similar: $2,000,000–$19,999,994 | $99,000,000 | 30 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Neon Therapeutics, Inc. | Director | Dec 13, 2017 | D/A | $106,000,001 similar: $2,000,000–$19,999,994 | $105,999,996 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Neon Therapeutics, Inc. | Director | Jan 11, 2017 | D | $70,000,000 similar: $829,831–$9,999,998 | $69,999,995 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Third Rock Ventures IV, L.P. group: Third Rock | Executive Officer Manager of the GPLLC. | Nov 2, 2016 | D | $600,000,000 similar: $155,000–$5,250,000 | $600,000,000 | 57 similar: 4–27 | $1,000,000 similar: $1,000–$100,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Sep 27, 2016 | D | $24,298,209 similar: $2,000,000–$19,999,994 | $24,298,209 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KALA BIO, Inc. | Director | Apr 13, 2016 | D | $67,921,796 similar: $2,000,000–$19,999,994 | $67,921,796 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Dec 15, 2015 | D | $55,824,208 similar: $2,000,000–$19,999,994 | $55,824,208 | 22 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Allena Pharmaceuticals, Inc. | Director | Dec 10, 2015 | D | $53,000,000 similar: $2,000,000–$19,999,994 | $51,442,139 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KALA BIO, Inc. | Director | Aug 19, 2015 | D | $6,999,999 similar: $2,000,000–$19,999,994 | $6,999,999 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Jounce Therapeutics, Inc. | Director | Apr 29, 2015 | D | $56,000,000 similar: $2,000,000–$19,999,994 | $56,000,000 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Allena Pharmaceuticals, Inc. | Director | Nov 13, 2014 | D | $27,000,000 similar: $1,694,259–$16,000,000 | $25,000,000 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Aug 5, 2014 | D | $5,000,000 similar: $2,000,000–$19,999,994 | $5,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KALA BIO, Inc. | Director | Apr 24, 2014 | D | $22,500,000 similar: $2,000,000–$19,999,994 | $22,500,000 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Third Rock Ventures III, L.P. | Executive Officer Manager of the General Partner's general partner. | Mar 25, 2013 | D | $500,000,000 similar: $155,000–$5,250,000 | $500,000,000 | 58 similar: 4–27 | $150,000 similar: $1,000–$100,000 |
| EDGAR ↗ | KALA BIO, Inc. | Director | Feb 28, 2013 | D | $11,500,118 similar: $2,000,000–$19,999,994 | $5,750,059 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Dec 14, 2012 | D | $13,000,000 similar: $1,694,259–$16,000,000 | $13,000,000 | 16 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | bluebird bio, Inc. group: Bluebird | Director | Jul 25, 2012 | D | $60,000,000 similar: $2,000,000–$19,999,994 | $60,000,000 | 17 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | KALA BIO, Inc. | Director | Mar 14, 2012 | D | $7,243,205 similar: $2,000,000–$19,999,994 | $7,243,205 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Dec 15, 2011 | D | $15,000,098 similar: $1,694,259–$16,000,000 | $15,000,098 | 19 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Jun 6, 2011 | D | $15,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | bluebird bio, Inc. group: Bluebird | Director | Apr 27, 2011 | D | $30,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | bluebird bio, Inc. group: Bluebird | Director | Apr 27, 2011 | D/A | $37,500,000 similar: $2,000,000–$19,999,994 | $37,500,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Nov 19, 2010 | D | $23,999,989 similar: $1,694,259–$16,000,000 | $16,499,994 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | KALA BIO, Inc. | Director | Nov 10, 2010 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Oct 13, 2010 | D | $1,499,999 similar: $1,694,259–$16,000,000 | $1,499,999 | 15 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Jun 9, 2010 | D | $5,000,000 similar: $1,694,259–$16,000,000 | $5,000,000 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CONSTELLATION PHARMACEUTICALS INC group: Third Rock | Director | Jun 2, 2010 | D | $22,250,000 similar: $2,000,000–$19,999,994 | $22,250,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Foundation Medicine, Inc. | Director | Apr 15, 2010 | D | $25,000,000 similar: $2,000,000–$19,999,994 | $7,000,000 | 1 similar: 2–16 | $7,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Third Rock Ventures II, L.P. | Executive Officer Member of the GP LLC | Apr 9, 2010 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | ALNARA PHARMACEUTICALS INC | Director | Feb 4, 2010 | D | $34,989,327 similar: $1,694,259–$16,000,000 | $19,994,431 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Dare Bioscience, Inc. | Director | Jul 27, 2009 | D | $10,000,000 similar: $1,694,259–$16,000,000 | $10,000,000 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); Biotechnology / 506(b) (3,253 filings); Other Health Care / 506(b) (4,189 filings); Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as Robert Tepper. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Robert Tepper appears on a new Form D, or when a court case or SEC action is matched to them. See plans →